The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Bisphosphonate‐associated osteonecrosis of mandibular and maxillary bone: An emerging oral complication of supportive cancer therapy
Abstract
BACKGROUND: The current report presented 17 patients with cancer with bone metastases and 1 patient with osteopenia who received treatment with bisphosphonates and who subsequently developed osteonecrosis of the mandible and/or maxilla. METHODS: The authors reviewed information on 18 patients who were referred to oral medicine or oral surgery specialists for evaluation and treatment of mandibular and/or maxillary bone necrosis from June 2002 to September 2004. To be included in the current review, patients must have been treated with either pamidronate or zoledronic acid to control or prevent metastatic disease, or with alendronate for osteoporosis. All patients with cancer had received chemotherapy while receiving bisphosphonate management. RESULTS: The 17 patients with cancer were receiving active medical care for a malignancy. Cancer treatment included a variety of chemotherapeutic agents. They presented with metastatic disease to bone and were treated intravenously with the bisphosphonates pamidronate or zoledronic acid for a mean time of 25 months (range, 4–41 mos). There were 14 females and 4 males with a mean age of 62 years (range, 37–74 yrs). Malignancies included breast carcinoma (n = 10), multiple myeloma (n = 3), prostate carcinoma (n = 1), ovarian carcinoma (n = 1), prostate carcinoma/lymphoma (n = 1), and breast/ovarian carcinoma (n = 1). One female patient with osteopenia received alendronate. The most common clinical osteonecrosis presentations included infection and necrotic bone in the mandible. Associated events included dental extractions, infection, and trauma. Two patients appeared to develop disease spontaneously, without any clinical or radiographic evidence of local pathology. Despite surgical intervention, antibiotic therapy, hyperbaric oxygen therapy, and topical use of chemotherapeutic mouth rinses, most of the lesions did not respond well to therapy. Discontinuation of bisphosphonate therapy did not assure healing. However, 1 patient with cancer healed after discontinuation of bisphosphonate therapy for 4 months. CONCLUSIONS: The findings in the patient population combined with recent literature reports suggested that bisphosphonates may contribute to the pathogenesis of the oral lesions. The risk factors and precise mechanism involved in the formation of the osteonecrosis are not known. This condition represents a new oral complication in patients with cancer and can be termed bisphosphonate‐associated osteonecrosis. Lesions in patients with osteoporosis are worrisome and need to be further evaluated. Cancer 2005. © 2005 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Marx, R. E. (2003) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/s0278-2391(03)00720-1 · Cited by 3,036
Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases
Ruggiero, S. L., Mehrotra, B., Rosenberg, T. J., & Engroff, S. L. (2004) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2004.02.004 · Cited by 2,057
Sato, M., Grasser, W., Endo, N., Akins, R., Simmons, H., Thompson, D. D., Golub, E., & Rodan, G. A. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115539 · Cited by 1,004
Hillner, B. E., Ingle, J. N., Chlebowski, R. T., Gralow, J., Yee, G. C., Janjan, N. A., Cauley, J. A., Blumenstein, B. A., Albain, K. S., Lipton, A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.017 · Cited by 970
Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid.
Wood, J., Bonjean, K., Ruetz, S., Bellahcène, A., Devy, L., Foidart, J. M., Castronovo, V., & Green, J. R. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.035295 · Cited by 854
Fournier, P. G. J., Boissier, S., Filleur, S., Guglielmi, J., Cabon, F., Colombel, M. C., & Clézardin, P. (2002) · PubMed · Cited by 646
Reuther, T., Schuster, T., Mende, U., & Kübler, A. (2003) · International Journal of Oral and Maxillofacial Surgery · doi:10.1054/ijom.2002.0332 · Cited by 492
Bisphosphanates and Oral Cavity Avascular Bone Necrosis
Migliorati, C. A. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.99.132 · Cited by 480
Self-citationBisphosphonates in Bone Disease: From the Laboratory to the Patient
Fleisch, H. A. (1995) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · Cited by 472
Bisphosphonate-Induced Osteopetrosis
Whyte, M. P., Wenkert, D., Clements, K. L., McAlister, W. H., & Mumm, S. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa023110 · Cited by 446
Cited by
Ruggiero, S. L., Dodson, T. B., Assael, L. A., Landesberg, R., Marx, R. E., & Mehrotra, B. (2009) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2009.01.009 · Cited by 1,328
Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws
Woo, S.-B., Hellstein, J. W., & Kalmar, J. R. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-10-200605160-00009 · Cited by 1,252
Ruggiero, S. L., Dodson, T. B., Aghaloo, T., Carlson, E. R., Ward, B. B., & Kademani, D. (2022) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2022.02.008 · Cited by 1,141
(2007) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2006.11.003 · Cited by 837
Marx, R. E., Cillo, J. E., & Ulloa, J. J. (2007) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2007.08.003 · Cited by 720
Osteonecrosis of the Jaw in Multiple Myeloma Patients: Clinical Features and Risk Factors
Badros, A., Weikel, D., Salama, A., Goloubeva, O., Schneider, A., Rapoport, A., Fenton, R., Gahres, N., Sausville, E., Ord, R., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.2465 · Cited by 593
Khosla, S. (2008) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2008.01.054 · Cited by 564
Ruggiero, S. L., Fantasia, J., & Carlson, E. (2006) · Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology · doi:10.1016/j.tripleo.2006.06.004 · Cited by 507
Ruggiero, S. L., Dodson, T. B., Assael, L. A., Landesberg, R., Marx, R. E., & Mehrotra, B. (2009) · Australian Endodontic Journal · doi:10.1111/j.1747-4477.2009.00213.x · Cited by 505
Managing the care of patients with bisphosphonate-associated osteonecrosis
MIGLIORATI, C. A., CASIGLIA, J., EPSTEIN, J., JACOBSEN, P. L., SIEGEL, M. A., & WOO, S.-B. (2005) · The Journal of the American Dental Association · doi:10.14219/jada.archive.2005.0108 · Cited by 468
Self-citationBisphosphonate Therapy for Osteoporosis: Benefits, Risks, and Drug Holiday
McClung, M., Harris, S. T., Miller, P. D., Bauer, D. C., Davison, K. S., Dian, L., Hanley, D. A., Kendler, D. L., Yuen, C. K., & Lewiecki, E. M. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2012.06.023 · Cited by 451
Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline
Yarom, N., Shapiro, C. L., Peterson, D. E., Van Poznak, C. H., Bohlke, K., Ruggiero, S. L., Migliorati, C. A., Khan, A., Morrison, A., Anderson, H., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01186 · Cited by 420
Self-citationKyle, R. A., Yee, G. C., Somerfield, M. R., Flynn, P. J., Halabi, S., Jagannath, S., Orlowski, R. Z., Roodman, D. G., Twilde, P., & Anderson, K. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.1269 · Cited by 409
Ripamonti, C. I., Maniezzo, M., Campa, T., Fagnoni, E., Brunelli, C., Saibene, G., Bareggi, C., Ascani, L., & Cislaghi, E. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn526 · Cited by 405
Fliefel, R., Tröltzsch, M., Kühnisch, J., Ehrenfeld, M., & Otto, S. (2015) · International Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.ijom.2015.01.026 · Cited by 363
Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment
Migliorati, C. A., Siegel, M. A., & Elting, L. S. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70726-4 · Cited by 342
Self-citationManagement of the adverse effects associated with intravenous bisphosphonates
Tanvetyanon, T., & Stiff, P. J. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj105 · Cited by 301
Pazianas, M., Miller, P., Blumentals, W. A., Bernal, M., & Kothawala, P. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.08.008 · Cited by 298
Bisphosphonate Associated Osteonecrosis of the Jaw
KHAN, A. A., SÁNDOR, G. K. B., DORE, E., MORRISON, A. D., ALSAHLI, M., AMIN, F., PETERS, E., HANLEY, D. A., CHAUDRY, S. R., LENTLE, B., et al. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.080759 · Cited by 280
Boonyapakorn, T., Schirmer, I., Reichart, P. A., Sturm, I., & Massenkeil, G. (2008) · Oral Oncology · doi:10.1016/j.oraloncology.2007.11.012 · Cited by 280
Yoneda, T., Hagino, H., Sugimoto, T., Ohta, H., Takahashi, S., Soen, S., Taguchi, A., Toyosawa, S., Nagata, T., & Urade, M. (2010) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-010-0162-7 · Cited by 272
Khan, A. A., Morrison, A., Kendler, D. L., Rizzoli, R., Hanley, D. A., Felsenberg, D., McCauley, L. K., O'Ryan, F., Reid, I. R., Ruggiero, S. L., et al. (2017) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2016.09.005 · Cited by 264
Raje, N. S., Anaissie, E., Kumar, S. K., Lonial, S., Martin, T., Gertz, M. A., Krishnan, A., Hari, P., Ludwig, H., O'Donnell, E., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00283-0 · Cited by 212
Bisphosphonates in multiple myeloma: a network meta-analysis
Mhaskar, R., Redzepovic, J., Wheatley, K., Clark, O. A. C., Miladinovic, B., Glasmacher, A., Kumar, A., & Djulbegovic, B. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003188.pub3 · Cited by 130
Metadata
- Authors
- Migliorati, C. A., Schubert, M. M., Peterson, D. E., & Seneda, L. M.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2005-06-17
- Volume
- 104
- Issue
- 1
- Pages
- 83-93
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2076157012
- Cited by
- 489
- References
- 26
- FWCI
- 28.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.